Cantor Fitzgerald reaffirmed overweight rating and Leerink Partners upgraded rating for Summit Therapeutics on September 16, 2026.
1 report, 1 independent
Updated Sep 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reaffirmed overweight rating and Leerink Partners upgraded rating for Summit Therapeutics on September 16, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Summit Therapeutics
biopharmaceutical company
Nothing else this week.